Can antioxidant vitamins avoid the cardiotoxicity of doxorubicin in treating breast cancer?

Cavalcanti, Iago Dillion Lima; Soares, José Cleberson Santos; Medeiros, Sandrelli Meridiana de Fátima Ramos dos Santos; Cavalcanti, Isabella Macário Ferro; Nogueira, Mariane Cajubá de Britto Lira

doi:10.1016/j.phanu.2021.100259

Cited by 6 publications

(6 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[30][31][32] Four systematic reviews studied vitamin E and the result were controversial (Table 2). [36][37][38][39] Levocarnitine: Five trials were included that had a total of 190 patients. All trials concluded that levocarnitine has a cardioprotective effect.…”

Section: Resultsmentioning

confidence: 99%

“…The majority of systematic reviews were of low quality according to the AMSTAR2 scale (Table 2). [36][37][38][39]46…”

Section: Quality Assessment Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

“…With the global trend in nutraceuticals and drug repurposing, a re-evaluation of the trials of these agents maybe worthwhile to reduce the cost of the burden of the cancer disease. 36,37,41 There is value in re-evaluating the use of vitamin E and levocarnitine as these are tolerable and safe in addition to their affordability and availability. 85…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Vitamin E and levocarnitine as prophylaxis against doxorubicin-induced cardio toxicity in the adult cancer patient: A review

Moustafa

Saka

Viljoen

et al. 2022

J Oncol Pharm Pract

View full text Add to dashboard Cite

Objective Doxorubicin, a component of the anthracycline group, is a highly effective in the treatment of hematologic and solid malignancies. Because of the cardiotoxic adverse effects, use is limited. Antioxidants may negate this anthracycline-induced cardiotoxicity, although the literature is not conclusive with regards to the cardioprotective benefits of antioxidants. This review assessed and mapped evidence of the efficacy of vitamin E and levocarnitine against doxorubicin-induced cardiotoxicity in adult cancer patients. Data Sources This review was based on the Arksey and O’Malley methodology. Potentially relevant literature in English published between January 1960 and April 2021 was identified through a database search. Oxford Quality Scoring System and AMSTR2 were used to assess the quality of trials and systematic reviews respectively, as well as the risks of potential bias. Data Summary Nineteen of the 10 268 (0.2%) articles from the initial search were included in the final analysis (12 clinical trials and 7 systematic reviews). Vitamin E was included in seven prospective clinical trials. Levocarnitine was included in five clinical trials as an individual agent and a single trial as a combination treatment. No trials could be found investigating the combination of vitamin E and levocarnitine in humans. Conclusions This review found that levocarnitine trials showed some cardioprotective effects but the results from vitamin E trials were controversial and inconclusive. Most of the trials reviewed had some shortcomings. Further investigations are therefore needed to determine the efficacy of vitamin E and levocarnitine in preventing doxorubicin-induced cardiotoxicity in adult cancer patients.

show abstract

Section: Resultsmentioning

confidence: 99%

“…The majority of systematic reviews were of low quality according to the AMSTAR2 scale (Table 2). [36][37][38][39]46…”

Section: Quality Assessment Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Vitamin E and levocarnitine as prophylaxis against doxorubicin-induced cardio toxicity in the adult cancer patient: A review

Moustafa

Saka

Viljoen

et al. 2022

J Oncol Pharm Pract

View full text Add to dashboard Cite

show abstract

“…In contrast to these findings, several clinical trials with vitamin E adjuvant therapy failed to protect against DOX-induced cardiotoxicity [ 140 ]. In light of a current review by Cavalcanti et al [ 141 ] and a systematic review published by Yasueda et al [ 22 ], we question the effectiveness of the self-decided gavage of antioxidant vitamins in the prevention of DOX-induced side effects.…”

Section: The Critical Role Of Nrf-2-keap I In the Interplay Between C...mentioning

confidence: 99%

The Self-Administered Use of Complementary and Alternative Medicine (CAM) Supplements and Antioxidants in Cancer Therapy and the Critical Role of Nrf-2—A Systematic Review

Kuchheuser

Birringer

2022

Antioxidants

View full text Add to dashboard Cite

Complementary and alternative medicine (CAM) supplements are widely used by cancer patients. Dietary supplements, vitamins and minerals, herbal remedies, and antioxidants are especially popular. In a systematic literature review, 37 studies, each including more than 1000 participants, on CAM, dietary supplement, and vitamin use among cancer patients were identified. Accordingly, cancer patients use antioxidants such as vitamin C (from 2.6% (United Kingdom) to 41.6% (United States)) and vitamin E (from 2.9% (China) to 48% (United States)). Dietary supplements and vitamins are taken for different reasons, but often during conventional cancer treatment involving chemotherapy or radiotherapy and in a self-decided manner without seeking medical advice from healthcare professionals. Drug–drug interactions with dietary supplements or vitamins involving multiple signaling pathways are well described. Since most of the anticancer drugs generate reactive oxygen species (ROS), an adaptive stress response of healthy and malignant cells, mainly driven by the Nrf-2-Keap I network, can be observed. On the one hand, healthy cells should be protected from ROS-overproducing chemotherapy and radiotherapy; on the other hand, ROS production in cancer cells is a “desirable side effect” during anticancer drug treatment. We here describe the paradoxical use of antioxidants and supplements during cancer therapy, possible interactions with anticancer drugs, and the involvement of the Nrf-2 transcription factor.

show abstract

Protective effect of Juglanin against doxorubicin-induced cognitive impairment in rats: Effect on oxidative, inflammatory and apoptotic machineries

et al. 2022

View full text Add to dashboard Cite

Can antioxidant vitamins avoid the cardiotoxicity of doxorubicin in treating breast cancer?

Cited by 6 publications

References 61 publications

Vitamin E and levocarnitine as prophylaxis against doxorubicin-induced cardio toxicity in the adult cancer patient: A review

Vitamin E and levocarnitine as prophylaxis against doxorubicin-induced cardio toxicity in the adult cancer patient: A review

The Self-Administered Use of Complementary and Alternative Medicine (CAM) Supplements and Antioxidants in Cancer Therapy and the Critical Role of Nrf-2—A Systematic Review

Protective effect of Juglanin against doxorubicin-induced cognitive impairment in rats: Effect on oxidative, inflammatory and apoptotic machineries

Contact Info

Product

Resources

About